Friday, 20 Sep 2019

You are here

EULAR: Tofacitinib Effective in Ankylosing Spondylitis

Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis. Both tofacitinib 5 and 10 mg BID demonstrated greater clinical efficacy compared with placebo as measured by ASDAS20 and ASDAS40 outcomes. Additionally, MRI imaging showed structural/inflammatory benefits in TOFA, but not placebo treated patients.

208 AS patients were randomised 1:1:1:1 to placebo or tofacitinib 2, 5 or 10 mg BID for 12 weeks plus 4 weeks follow-up. There were 196 completers, and 87% were HLA-B27 positive and 81% were white. The mean disease duration was 6.3 years and the mean baseline BASDAI was 6.7. 

Treatment with TOFA (5 mg or 10 mg bid) yielded better ASDAS20 scores that were 23% adn 27% better than placebo rates (~40%).  BASDAI results were similar.  The ineffective 2 mg bid dose of TOFA had results comparable to placebo. No new safety signals were raised by this trial. 

MRI changes were assessed by SPARCC scoring of the sacroiliac joints and spine. Overall, the 5mg and 10 mg TOFA group yielded significantly less change and inflammation in the spine.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.